BioCryst Pharmaceuticals Inc (BCRX)
4.44
-0.06
(-1.33%)
USD |
NASDAQ |
Apr 19, 16:00
4.43
-0.01
(-0.23%)
After-Hours: 20:00
BioCryst Pharmaceuticals Enterprise Value: 1.350B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.350B |
| April 17, 2024 | 1.366B |
| April 16, 2024 | 1.373B |
| April 15, 2024 | 1.385B |
| April 12, 2024 | 1.406B |
| April 11, 2024 | 1.474B |
| April 10, 2024 | 1.426B |
| April 09, 2024 | 1.412B |
| April 08, 2024 | 1.373B |
| April 05, 2024 | 1.371B |
| April 04, 2024 | 1.371B |
| April 03, 2024 | 1.397B |
| April 02, 2024 | 1.389B |
| April 01, 2024 | 1.463B |
| March 28, 2024 | 1.470B |
| March 27, 2024 | 1.484B |
| March 26, 2024 | 1.455B |
| March 25, 2024 | 1.434B |
| March 22, 2024 | 1.455B |
| March 21, 2024 | 1.554B |
| March 20, 2024 | 1.550B |
| March 19, 2024 | 1.527B |
| March 18, 2024 | 1.467B |
| March 15, 2024 | 1.453B |
| March 14, 2024 | 1.430B |
| Date | Value |
|---|---|
| March 13, 2024 | 1.482B |
| March 12, 2024 | 1.482B |
| March 11, 2024 | 1.519B |
| March 08, 2024 | 1.542B |
| March 07, 2024 | 1.490B |
| March 06, 2024 | 1.496B |
| March 05, 2024 | 1.538B |
| March 04, 2024 | 1.558B |
| March 01, 2024 | 1.581B |
| February 29, 2024 | 1.583B |
| February 28, 2024 | 1.599B |
| February 27, 2024 | 1.632B |
| February 26, 2024 | 1.616B |
| February 23, 2024 | 1.599B |
| February 22, 2024 | 1.620B |
| February 21, 2024 | 1.585B |
| February 20, 2024 | 1.620B |
| February 16, 2024 | 1.640B |
| February 15, 2024 | 1.583B |
| February 14, 2024 | 1.568B |
| February 13, 2024 | 1.517B |
| February 12, 2024 | 1.647B |
| February 09, 2024 | 1.626B |
| February 08, 2024 | 1.517B |
| February 07, 2024 | 1.513B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
186.14M
Minimum
Nov 14 2019
3.727B
Maximum
Feb 16 2022
1.592B
Average
1.739B
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 11.42M |
| Perspective Therapeutics Inc | 855.25M |
| Protalix BioTherapeutics Inc | 58.24M |
| Electromed Inc | 109.52M |
| Armata Pharmaceuticals Inc | 160.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.73M |
| Revenue (Quarterly) | 93.40M |
| Total Expenses (Quarterly) | 136.07M |
| EPS Diluted (Quarterly) | -0.31 |
| Gross Profit Margin (Quarterly) | 98.25% |
| Profit Margin (Quarterly) | -66.09% |
| Earnings Yield | -26.58% |
| Normalized Earnings Yield | -23.74 |